Although it has only been approved by the US-FDA for the treatment of type 2 diabetes at present, a wide variety of GLP-1 receptor agonists have become attractive candidate drugs for the treatment of MAFLD due to their metabolic benefits. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.